Loading...
TGAT
V3VGn
Market cap58mUSD
Oct 18, Last price  
15.60EUR
Name

Vita 34 AG

Chart & Performance

D1W1MN
TGAT:V3VGn chart
P/E
—
P/S
2.80
EPS
—
Div Yield, %
—
Shrs. gr., 5y
33.58%
Rev. gr., 5y
34.45%
Revenues
88m
+7.29%
015,426,00014,957,00015,097,00016,963,00016,001,00013,603,00013,554,00013,786,00014,169,00016,290,00019,186,00020,410,00020,247,00020,070,00028,418,00068,940,00077,062,00082,184,00088,173,000
Net income
-6m
L-48.06%
0-1,185,000-1,712,000596,000349,0001,191,000-579,000838,0001,100,0001,979,000408,000-322,000828,0001,350,0001,449,000-3,926,000-27,385,000-1,865,000-12,136,000-6,303,000
CFO
4m
-55.19%
-341,000-1,664,000-2,939,0001,149,0001,008,000-683,0002,039,0001,775,0001,055,0002,590,0002,287,0001,530,0004,598,0006,318,0003,980,0002,727,000-4,486,0009,154,0008,655,0003,878,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

FamiCord AG engages in the collection, logistics, processing, and storage of stem cells from umbilical cord blood, umbilical cord tissue, and other postnatal tissues, serving as a full-service provider for cryopreservation. It also engages in the development of products and drugs derived from cells, tissues, and blood for medical applications. Additionally, FamiCord is active in Cell & Gene therapies and operates as a CDMO. The company was founded by Eberhard F. Lampeter on April 28, 1997 and is headquartered in Leipzig, Germany.
URL
https://www.vita34.de/
IPO date
Nov 21, 2007
Employees
815
Domiciled in
DE
Incorporated in
DE

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT